GB0410103D0 - New method - Google Patents

New method

Info

Publication number
GB0410103D0
GB0410103D0 GBGB0410103.6A GB0410103A GB0410103D0 GB 0410103 D0 GB0410103 D0 GB 0410103D0 GB 0410103 A GB0410103 A GB 0410103A GB 0410103 D0 GB0410103 D0 GB 0410103D0
Authority
GB
United Kingdom
Prior art keywords
new method
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0410103.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolipox AB
Original Assignee
Biolipox AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox AB filed Critical Biolipox AB
Priority to GBGB0410103.6A priority Critical patent/GB0410103D0/en
Publication of GB0410103D0 publication Critical patent/GB0410103D0/en
Priority to EP05741939A priority patent/EP1742622A1/en
Priority to PCT/GB2005/001724 priority patent/WO2005107725A1/en
Priority to JP2007512321A priority patent/JP2007536359A/ja
Priority to US11/579,474 priority patent/US20080081835A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0410103.6A 2004-05-06 2004-05-06 New method Ceased GB0410103D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0410103.6A GB0410103D0 (en) 2004-05-06 2004-05-06 New method
EP05741939A EP1742622A1 (en) 2004-05-06 2005-05-05 Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas
PCT/GB2005/001724 WO2005107725A1 (en) 2004-05-06 2005-05-05 Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas
JP2007512321A JP2007536359A (ja) 2004-05-06 2005-05-05 Ｂ細胞の白血病及びリンパ腫の治療のためのｌｔｂ４インヒビターの使用
US11/579,474 US20080081835A1 (en) 2004-05-06 2005-05-05 Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0410103.6A GB0410103D0 (en) 2004-05-06 2004-05-06 New method

Publications (1)

Publication Number Publication Date
GB0410103D0 true GB0410103D0 (en) 2004-06-09

Family

ID=32482771

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0410103.6A Ceased GB0410103D0 (en) 2004-05-06 2004-05-06 New method

Country Status (5)

Country Link
US (1) US20080081835A1 (enExample)
EP (1) EP1742622A1 (enExample)
JP (1) JP2007536359A (enExample)
GB (1) GB0410103D0 (enExample)
WO (1) WO2005107725A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110245107A1 (en) * 2008-01-18 2011-10-06 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, amd modulation of human th17 cells
US9732320B2 (en) 2008-01-18 2017-08-15 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human TH17 cells
EP2278947A4 (en) * 2008-05-21 2013-11-06 Teikoku Pharma Usa Inc TREATMENT OF DYSMENORRHEA BY TRANSDERMAL ADMINISTRATION OF NON-TEMPEROIDAL INFLAMMATORY DRUGS
GB0810011D0 (en) * 2008-06-02 2008-07-09 Jackson William P 5-Lipoxygenase inhibitors
KR102368958B1 (ko) 2013-12-20 2022-02-28 노파르티스 아게 Lta4h 억제제로서의 헤테로아릴 부탄산 유도체
CN115068486A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 乳香酸类化合物作为ltb4受体抑制剂的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2185448A1 (en) * 1994-03-14 1995-09-21 James L. Mulshine Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
AU7856600A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
AU1595101A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1917101A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
DE60319156T2 (de) * 2002-02-08 2009-01-29 F. Hoffmann-La Roche Ag Methode zur Identifizierung von Verbindungen, die die Knochenmineral-Dichte erhöhen
JP2003252763A (ja) * 2002-02-27 2003-09-10 Yuichiro Kamikawa 抗腫瘍剤
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2004099783A2 (en) * 2003-05-06 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)

Also Published As

Publication number Publication date
US20080081835A1 (en) 2008-04-03
EP1742622A1 (en) 2007-01-17
WO2005107725A1 (en) 2005-11-17
JP2007536359A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
GB0420061D0 (en) Method
GB0402639D0 (en) Method
GB0422733D0 (en) Method
GB0410478D0 (en) Method
GB0415009D0 (en) Method
GB0418651D0 (en) Method
GB0419419D0 (en) Method
GB0422730D0 (en) Method
GB0412659D0 (en) Method
GB0412672D0 (en) Method
GB0410103D0 (en) New method
GB0420815D0 (en) Method
GB0423871D0 (en) Method
GB0414787D0 (en) Method
GB0405751D0 (en) Method
GB0419405D0 (en) Method
GB0428327D0 (en) Method
GB0415081D0 (en) Method
GB0427916D0 (en) Method
GB0413714D0 (en) Method
GB0402358D0 (en) Method
GB0410872D0 (en) Method
GB0422881D0 (en) Method
GB0420170D0 (en) Method
GB0425832D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)